Key Takeaways
INmune Bio Inc. (NASDAQ: INMB) shares rose more than 10% after the company announced its novel Alzheimer’s treatment, XPro™, showed positive results in a Phase 2 trial, offering a differentiated approach that targets neuroinflammation without the brain swelling seen in some competing therapies.
"We believe XPro has the potential to significantly alter the trajectory of this devastating disease," David Moss, CEO of INmune Bio, said. "This recognition underscores the urgent need for innovative treatments that address the underlying neuroinflammation associated with early Alzheimer's."
The biotech company’s stock jumped 10.3% in premarket trading after it announced the results from its MINDFuL trial were published in the peer-reviewed journal NPJ Dementia. The study found XPro showed a "directionally consistent benefit" across cognitive, functional, and biomarker endpoints in a subgroup of Alzheimer's patients with inflammation. Crucially, no cases of amyloid-related imaging abnormalities (ARIA), a side effect that has plagued anti-amyloid therapies, were observed.
The positive data provides a new path forward in a field dominated by amyloid- and tau-targeting drugs. With an estimated 7.4 million Americans living with Alzheimer's, and no approved therapies targeting neuroinflammation, XPro's unique mechanism could address a significant unmet need. The advance comes just a day after the U.S. Food and Drug Administration granted the drug Fast Track designation, which will expedite its review.
XPro is a selective soluble TNF (sTNF) inhibitor. Unlike broad TNF inhibitors, it is designed to neutralize the pro-inflammatory sTNF protein while preserving transmembrane TNF (tmTNF), which is essential for immune function and brain repair. This selective approach is intended to reduce the neuroinflammation that is now recognized as a key driver of cognitive decline in a large subset of Alzheimer's patients.
The MINDFuL trial's success in a specific, biologically-defined group of patients—those with early Alzheimer's and biomarkers for inflammation—highlights a shift towards precision medicine in neurodegenerative disease. INmune Bio plans to carry this enrichment strategy into a seamless Phase 2b/3 registrational program.
The positive results for XPro arrive as other companies pursue different targets for Alzheimer's. Biogen Inc. (Nasdaq: BIIB), for example, recently announced positive Phase 2 results for its tau-targeting drug, diranersen. While also showing cognitive benefits, diranersen works by reducing the production of tau protein, another hallmark of the disease. The differing mechanisms of XPro and diranersen underscore a multi-pronged industry attack on the complex disease.
INmune Bio's cash runway was not disclosed in the announcement. The company is now positioned to execute its pivotal trial, which will be critical for validating the drug's efficacy and safety in a larger population ahead of a potential regulatory submission.
This article is for informational purposes only and does not constitute investment advice.
